These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 10493280

  • 1. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 5. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 21; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 6. A risk-benefit assessment of iron-chelation therapy.
    Porter JB.
    Drug Saf; 1997 Dec 21; 17(6):407-21. PubMed ID: 9429839
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Dec 21; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 9. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 21; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

  • 10. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 21; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 11. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct 21; 9(49):131-5. PubMed ID: 11603411
    [Abstract] [Full Text] [Related]

  • 12. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 21; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 13. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 14. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 15. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.
    Cochrane Database Syst Rev; 2005 Oct 19; (4):CD004450. PubMed ID: 16235363
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S.
    BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857
    [Abstract] [Full Text] [Related]

  • 18. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2008 Feb 25; 10(1):12. PubMed ID: 18298856
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
    Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, Spino M.
    Mutagenesis; 2003 Sep 25; 18(5):457-63. PubMed ID: 12960415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.